DrugInformations.org

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary results of a Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). In the healthy volunteer study, ANA598 was well tolerated at all doses analyzed to date and no serious adverse events were reported.

More: continued here

No Comments »

The pathogenic mechanisms implicated in the failure of the intestinal barrier in cirrhosis have not been fully elucidated as yet and remains to be investigated. A research article to be published in the World Journal of Gastroenterology addresses this problem. The research team led by Dr. Shin and Dr.

More: continued here

No Comments »

Celsion Corporation (NASDAQ: CLSN) announced today that its global Phase III Primary Liver Cancer trial is proceeding as planned.

More: continued here

No Comments »

A revolutionary new ultrasonic treatment for liver and kidney cancer offers a surgery-free procedure for patients in the UK. Ultrasound is high frequency sound beyond the range of human hearing and has been employed in a variety of ways in the medical field including, in diagnostics to look inside the body and observe a growing foetus, in physiotherapy as a tool to aid the rejuvenation of muscles and pain control, and now, in the treatment of tumours.

More: continued here

No Comments »

Hepatocellular carcinoma (HCC) is the fifth most common cancer with more than 1 million fatalities occurring annually worldwide. Nowadays in China, the essential oil of Curcuma wenyujin (CWO) has been used as an injection to cure paediatric diseases such as acute upper respiratory infections, viral myocarditis and acute pneumonia. The inhibitory effects of CWO on the SMMC-7721 cell line, cervical cell, L615 cell and K562 cell line growth have been reported.

More: continued here

No Comments »

Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells — called senescence — is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.

More: continued here

No Comments »

Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV). Chronic hepatitis B is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.

More: continued here

No Comments »

ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for living.

More: continued here

No Comments »

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of Entecavir and Telbivudine for the treatment of chronic hepatitis B. NICE produced these two pieces of guidance as part of its rapid single technology appraisal (STA) work programme.

More: continued here

No Comments »

Patient groups are today calling on the Government to vaccinate all British children against Hepatitis B - a life threatening disease, 50 times more infectious than HIV. Chronic Hepatitis B can develop into potentially fatal conditions such as liver cancer and cirrhosis. It affects more than 325,000 patients in the UK alone, and once contracted cannot be cured. However, with a simple and effective vaccine, it can be prevented.

More: continued here

No Comments »